 "Lupin recieves USFDA nod to market generic anthelmintic tablets")
Drug firm Lupin on Thursday said it had received an approval from the US health regulator to market its generic anthelmintic Albendazole tablets.
The company has received approval to market its Albendazole tablets USP, 200 mg, from the United States Food and Drug Administration (USFDA), Lupin said in a statement.
The product is a generic version of Impax Laboratories Inc's Albenzatablets in the same strength, it added.
According to IQVIA MAT April 2020 data, Albendazole tablets had an annual sales of around $34 million in the US, Lupin said.
"The tablets are indicated for treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm and cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm," it added.
Shares of Lupin closed at Rs 920.45per scrip on the BSE, down 0.88per cent over previous close.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%